lobbying_activities: 2032785

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2032785	f43ce5e2-d6b8-48ee-9b46-f0c00968b8ec	3A	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	3457	AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS	2017	third_quarter	PHA	Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Communication with FDA on Generic Drug User Fee Act, Prescription Drug user Fee Act, Biosimilar User Fee Act, and electronic drug information. Contact on manufacturing gaming REMS to gain market advantage and drug importation. Communication with Congress on off-label use. Contact on the 340B program.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE		130000	0	0	2017-10-19T11:02:15.820000-04:00